What question did this study set out to answer?

This study investigates the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS) in older patients with relapsed or refractory large B-cell lymphoma treated with CAR-T therapy.

April 4, 2026Transplantation and Cellular TherapyOpen Access

Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study

View Full Paper

Ask AI

Bookmark

Authors

ATAung M. TunUniversity of Kansas RPRomil PatelThe University of Texas MD Anderson Cancer Center FSFrederique St-PierreNorthwestern University

Discussion

Member takes

Implication

Multicenter study reveals increased neurotoxicity risk linked to frailty and performance status in older lymphoma patients treated with CAR-T therapy, suggesting better candidate selection is vital.

Key Points

This study investigates the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS) in older patients with relapsed or refractory large B-cell lymphoma treated with CAR-T therapy.
Retrospective multicenter analysis of older patients (≥65 years) with relapsed or refractory large B-cell lymphoma
Assessment of cumulative estimates of ICANS within 30 days using competing risks for deaths/progressions
Evaluation of risk factors including ECOG performance status and LDH levels
In the study, 224 older patients were analyzed, with a median age of 71 years.
30-day estimates indicated 50.9% incidence of all grade ICANS and 29.8% for grade ≥3 ICANS.
Elevated LDH and poor performance status were associated with higher risks of grade ≥3 ICANS.

Cite This Study

Tun et al. (2026) studied this question.

synapsesocial.com/papers/69d0af52659487ece0fa52f9 https://doi.org/10.1016/j.jtct.2026.03.041

View Full Paper

Ask AI

Bookmark

Implication

Multicenter study reveals increased neurotoxicity risk linked to frailty and performance status in older lymphoma patients treated with CAR-T therapy, suggesting better candidate selection is vital.

Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study

Discussion

Member takes

Implication

Key Points

Cite This Study

Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider